Moderna raises its revenue outlook — but all eyes are on what happens next with its experimental cancer vaccine

The company lifted its revenue outlook for the year, saying it expects revenue to grow as much as 25% in 2026.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Every article behind this summary — 1 article from 1 outlet